Abstract:
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin or an analogue thereof, and nonG is an amino acid other than glycine.
Abstract:
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.
Abstract:
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.
Abstract:
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention , at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin or an analogue thereof, and nonG is an amino acid other than glyci ne.
Abstract:
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin or an analogue thereof, and nonG is an amino acid other than glycine.
Abstract:
Una unidad peptídica que comprende una secuencia seleccionada del grupo que consiste en péptido 0002-27 HQKRGCitGWSRAA, péptido 0002-29 HQRRVCitGWSRAA, péptido 0002-31 HQRRTCitGGSRAA, péptido 0002-32 HQRKWCitGASRAA, péptido 0002- 36 HQFRFCitGCitSRAA, péptido 0002-37 HQKWRCitGRSCitAA y péptido 0002-63 HQFRFCitGWSRAA.
Abstract:
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.
Abstract:
LA PRESENTE INVENCION SE REFIERE A UN PEPTIDO DERIVADO DE UN ANTIGENO RECONOCIDO POR AUTOANTICUERPOS; DICHO PEPTIDO REACCIONA CON ANTICUERPOS AUTOINMUNES QUE PROCEDEN DE UN PACIENTE QUE PADECE DE POLIARTRITIS REUMATOIDE. EL PEPTIDO DE ESTA INVENCION TIENE UN RESTO ARGININO MODIFICADO. ESTA INVENCION SE REFIERE TAMBIEN A UNOS ANTICUERPOS DIRIGIDOS CONTRA ESTE PEPTIDO, ASI COMO A UN PROCEDIMIENTO DE DETECCION DE ANTICUERPOS AUTOINMUNES.
Abstract:
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin or an analogue thereof, and nonG is an amino acid other than glycine.